NCT02275533 2026-03-19
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
24 trialsNCT03244384 2026-03-19
AMBASSADOR
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT01251861 2026-03-18
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
NCT02193282 2026-03-18
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02194738 2026-03-18
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
National Cancer Institute (NCI)
Phase NA Active not recruiting
NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03811015 2026-03-18
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT05343936 2026-03-18
Evaluation of an Active Surveillance Protocol for Prostate Cancer in the Brazilian Population
Hospital Moinhos de Vento
Active not recruiting
NCT02954874 2026-03-17
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT03055013 2026-03-17
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT00003641 2026-02-25
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT05333874 2026-02-09
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Active not recruiting
NCT05710406 2026-01-26
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 2/3 Active not recruiting
NCT02914873 2026-01-20
PCASTT
Uppsala University
Phase NA Active not recruiting
NCT06411938 2026-01-16
Merck-3
Indiana University
Phase NA Active not recruiting
NCT02176967 2025-12-22
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT03533582 2025-12-22
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
Children's Oncology Group
Phase 3 Active not recruiting
NCT02201992 2025-12-19
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT01169337 2025-11-25
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04216290 2025-11-12
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04519879 2025-10-29
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CA
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01096368 2025-10-27
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Children's Oncology Group
Phase 3 Active not recruiting
NCT04068103 2025-05-07
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
NRG Oncology
Phase 2/3 Active not recruiting